Cardiopulmonary Exercise Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cardiopulmonary exercise testing market size was valued at USD 1.47 billion in 2025 and is estimated to grow from USD 1.63 billion in 2026 to reach USD 2.71 billion by 2031, at a CAGR of 10.74% during the forecast period (2026-2031). This report is Segmented by Product (Cardiopulmonary Exercise Testing Systems, Metabolic Carts, and More), Application (Clinical Diagnostics, Pre-Operative Assessment, and More), Indication (Cardiovascular Diseases, Respiratory Diseases, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Cardiopulmonary Exercise Testing Market Trends and Insights

Rising Burden of Cardiovascular and Respiratory Disease

The cardiopulmonary exercise testing market sits at the point where cardiovascular and respiratory disease management now overlap more often in routine care. The World Health Organization reported 19.8 million cardiovascular disease deaths in 2022, equal to 32% of all global deaths, and more than three-quarters of those deaths occurred in low and middle-income countries, which still leaves substantial room for CPET expansion where penetration is low. The American Heart Association’s 2025 statistical update also showed that growing absolute incidence and better survival are extending the number of patients who need long-term functional monitoring instead of only acute treatment. This matters for the cardiopulmonary exercise testing market because more patients now live long enough to require repeated assessment of exercise tolerance, ventilatory response, and treatment recovery across several care settings. The same pattern supports follow-up demand in cardiac rehabilitation, where exercise prescription depends on measurable physiologic thresholds instead of generalized activity plans. A 2025 study in the European Journal of Preventive Cardiology found that patients with at least a 5% gain in VO₂ peak after 1 year of phase III rehabilitation had better composite outcomes, which strengthens the case for serial testing rather than a single baseline evaluation.

Expansion of Pre-Operative Risk Stratification Use Cases

The cardiopulmonary exercise testing market is also being supported by the wider use of CPET in surgical risk assessment at large hospitals and academic centers. A 2025 systematic review in the British Journal of Anesthesia Open found that submaximal CPET measures, especially the VE/VCO₂ slope, were independently linked to early postoperative complications across abdominal cancer populations, and values above 38 were tied to higher complication risk after esophageal cancer surgery. A separate 2025 study in PLOS Digital Health used machine learning on preoperative CPET data and showed that cardiorespiratory fitness variables can reveal nonlinear risk thresholds that are not captured through static clinical measures alone. These findings are widening the role of the cardiopulmonary exercise testing market from selected high-risk cases to more standardized use in thoracic, abdominal, and oncologic surgical pathways. The demand effect is not limited to full maximal testing because shorter protocols are also becoming more practical for presurgical clinics with heavy throughput. A 2025 JMIR Perioperative Medicine feasibility study showed that an 18-minute submaximal CPET protocol was technically reliable and acceptable in a high-volume clinic, with 96% of older adults reporting tolerable exertion, which lowers workflow barriers for broader use.

High Capital Cost of CPET Equipment and Service Contracts

The cardiopulmonary exercise testing market still faces a meaningful adoption barrier because a full CPET laboratory setup requires a large upfront investment. The input draft states that integrated systems combining a metabolic cart, calibrated ergometer, 12-lead ECG, and software can cost USD 50,000 to USD 150,000 per installation, and annual service contracts can add another 10% to 15% to ownership costs. That burden slows purchasing in community and secondary hospitals, especially where administrators compare CPET with other capital needs that appear more urgent or serve broader patient volumes. The restraint is stronger in low and middle-income countries because thin reimbursement and limited equipment financing make it harder to justify long payback periods. Ongoing calibration, sensor replacement, and mask or mouthpiece consumables also raise the total cost of ownership and create budget pressure in public systems operating under fixed diagnostic tariffs. This slows replacement cycles as well, which means older installed systems stay in use longer and newer platforms enter the cardiopulmonary exercise testing market more gradually.

Other drivers and restraints analyzed in the detailed report include:

• Artificial Intelligence Assisted Test Interpretation
• Portable and Compact CPET Adoption in Outpatient Settings
• Need for Specialized Training and Standardized Protocol Adherence

Segment Analysis

CPET systems held 42.37% of global product revenue in 2025, which kept them as the leading product group within the cardiopulmonary exercise testing market. Their lead reflects the fact that hospitals still prefer integrated platforms that combine gas exchange analysis, ergometers, ECG capability, and interpretation software in a single clinical setup. These systems remain the reference standard for diagnostic depth and are widely used in heart failure prognosis, transplant workup, pulmonary hypertension management, and other guideline-based use cases. The product mix also shows how strongly hospital cardiology and pulmonology labs continue to shape purchasing patterns in the cardiopulmonary exercise testing market. GE HealthCare’s CASE platform update with CardioSoft technology, presented at ACC 2025, reflects the direction of this category because buyers increasingly want digital workflow integration and direct compatibility with hospital information systems.

Metabolic carts are projected to expand at an 11.34% CAGR from 2026 to 2031, which makes them the fastest-growing product group in the cardiopulmonary exercise testing market. Their faster growth reflects demand from outpatient rehabilitation programs, specialist clinics, and diagnostic centers that want leaner configurations than full laboratory systems. ECG and blood pressure monitoring systems remain more standardized products, but they still benefit from mandatory integration in most CPET workflows and continue to support recurring revenue through consumables and software-linked functionality. The broader “others” group, which includes wearable metabolic monitors, remote spirometry accessories, and pulse oximetry modules, remains smaller but strategically relevant as sensor-fusion models develop across the cardiopulmonary exercise testing market. Regulation is also shaping product choices because most CPET gas analyzers in the United States fall under FDA device classification rules in 21 CFR Part 868, while the CMS billing update to Article A56784 affects how hospitals align reimbursable pulmonary stress testing configurations with procurement plans.

Clinical diagnostics accounted for 43.68% share of the cardiopulmonary exercise testing market size in 2025, which kept it as the largest application area. That position reflects CPET’s role as a leading tool in evaluating unexplained dyspnea, classifying heart failure severity, and assessing coronary artery disease in hospital cardiology practice. These use cases generate large testing volumes because they sit close to referral hubs and established specialist pathways. Pre-operative assessment also holds an important share because thoracic surgery and major abdominal oncology programs are using standardized CPET workup more often before complex procedures. Research remains smaller in volume, but it still supports premium device configurations and advanced software demand because sponsored studies require detailed protocols, structured outputs, and reproducible measurements.

Pulmonary rehabilitation is projected to grow at an 11.89% CAGR from 2026 to 2031, making it the fastest-expanding application in the cardiopulmonary exercise testing market. Its rise reflects formal rehabilitation guidance for COPD, heart failure, and post-COVID functional limitation, where exercise prescription is stronger when based on measured physiologic thresholds rather than generic endurance plans. A 2025 BMC Cardiovascular Disorders study found that CPET-guided exercise training improved peak VO₂, anaerobic threshold, and METS in heart failure patients after acute myocardial infarction who received sacubitril or valsartan therapy. That result matters because it supports a combined model in which pharmacotherapy and rehabilitation monitoring reinforce each other over repeated care episodes. The cardiopulmonary exercise testing market therefore benefits from rehabilitation demand differently than from pre-operative assessment, since repeated follow-up creates more durable testing utilization than a single diagnostic event.

Complete Report Scope:

• By Product
  • Cardiopulmonary Exercise Testing (CPET) Systems
  • Metabolic Carts
  • ECG & Blood Pressure Monitoring Systems
  • Others
• By Application
  • Clinical Diagnostics
  • Pre-operative Assessment
  • Research Applications
  • Pulmonary Rehabilitation
  • Others
• By Indication
  • Cardiovascular Diseases
  • Respiratory Diseases
  • Heart Failure
  • Pulmonary Hypertension
  • Others
• By End User
  • Hospitals
  • Diagnostic Centers
  • Specialty Cardiology & Pulmonology Clinics
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 38.46% of the cardiopulmonary exercise testing market share in 2025, which kept the region in the leading position. The region benefits from a dense base of academic cardiology and pulmonology programs, broad familiarity with exercise-based diagnostics, and stronger payer coverage across hospital and outpatient settings. The United States remains the regional anchor because several major platform developers, including GE HealthCare, MGC Diagnostics, SunTech Medical, and Masimo, are based there and support local product visibility, service capacity, and workflow innovation. Canada is emerging as a secondary growth market because aging demographics and health technology assessment activity are improving the case for broader cardiopulmonary monitoring. Mexico remains slower to develop because insurance coverage is more fragmented, and specialist CPET infrastructure is still concentrated in major urban centers.

Europe is the second-largest regional bloc in the cardiopulmonary exercise testing market, supported by strong healthcare infrastructure and established reimbursement pathways for cardiopulmonary diagnostics. Germany holds a solid position because of its statutory insurance depth and the domestic presence of SCHILLER AG and CORTEX Biophysik, while the United Kingdom sustains high institutional testing volumes through NHS pre-operative assessment networks that are tied to surgical outcomes initiatives. Even within Europe, utilization is not uniform, and a 2026 survey from the Portuguese Society of Cardiology showed that access gaps and insufficient residency training still limit fuller adoption despite mature infrastructure. The EU Medical Device Regulation timeline also affects distributor and OEM strategy because next-generation systems with software and AI modules require careful compliance planning before wider rollout.

Asia-Pacific is projected to expand at a 14.62% CAGR from 2026 to 2031, which makes it the fastest-growing region in the cardiopulmonary exercise testing market. China and India are driving that pace through hospital capacity expansion and stronger integration of cardiopulmonary diagnostics into national non-communicable disease programs. Japan is technically advanced, but a Journal of Arrhythmia study found that only 21% of facilities had introduced CPET equipment, and staffing limitations remained a key brake on utilization even where devices were available. South Korea and Australia add depth to regional growth because both have established cardiology networks and expanding outpatient rehabilitation infrastructure. The Middle East and Africa remain smaller in absolute size, but GCC countries are investing in tertiary care capacity and Saudi data showed a 14.1% increase in utilization versus 2 decades earlier even as equipment cost and technician shortages persisted. South America is still at an earlier stage, with adoption concentrated in large private hospital networks and research institutions in cities such as São Paulo, Buenos Aires, and Bogotá, while public sector uptake remains tied to budget cycles and reimbursement gaps.

List of Companies Covered in this Report:

• Allengers
• Cardinal Health
• Cardioline
• CORTEX Biophysik
• Cosmed
• Ergoline GmbH
• Fukuda Denshi Co., Ltd.
• GE Healthcare
• Geratherm Medical
• Halma
• Innomed Medical Zrt.
• Koninklijke Philips
• Masimo
• Medisoft SA
• MGC Diagnostics
• Nihon Kohden
• Schiller
• Spacelabs Healthcare
• SunTech Medical, Inc.
• Vyaire Medical
• Welch Allyn

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support